Towards evidence-based response criteria for cancer immunotherapy

Elena Garralda, Scott A. Laurie, Lesley Seymour and Elisabeth G. E. Vries ()
Additional contact information
Elena Garralda: Vall d’Hebron Institute of Oncology
Scott A. Laurie: The Ottawa Hospital Cancer Centre
Lesley Seymour: Queens University, Cancer Centre of South Eastern Ontario
Elisabeth G. E. Vries: University of Groningen

Nature Communications, 2023, vol. 14, issue 1, 1-4

Abstract: Early detection of immunotherapy-induced tumor response is of major benefit for patients but can be complicated by therapy-induced pseudoprogression. A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1). Here we describe which next steps are required to test its validity and how novel approaches for response criteria might be developed and included.

Date: 2023
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-38837-3 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-38837-3

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-38837-3

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().